Chimeric antigen receptor (CAR) T-cell ("Living Drug") immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside and back to bench – constructing, manufacturing and obtaining FDA approvals for clinical grade CARs and vectors, developing universal algorithms across multiple CAR T-cell clinical trials for the treatment and management of complications, and conducting world-class correlative science.
MSK faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies (CARs, TCRs, NKs), both for hematologic malignancies and solid tumors.
The target audience includes medical oncologists and oncology fellows, basic scientists, research fellows, nurses, clinical trial research staff, immunologists, and surgeons with an interest in tumor immunology and immunotherapy.
Thursday, March 14 at 8:00am to 6:00pm
Zuckerman Research Center, 417 East 68th Street, New York, NY